Opdivo (nivolumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Opdivo (nivolumab) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to the rising prevalence of cancer, increased investment in research and development capabilities, growing healthcare facility investments, a higher incidence of non-small cell lung cancer, and increased healthcare expenditure on capital equipment.

The expected growth during the forecast period is driven by factors such as the growing acceptance of immunotherapy, an enhanced understanding of its benefits, increased healthcare spending on capital equipment, expanding uses of nivolumab for various indications, and a rising preference for immunotherapy treatments. Key trends for the forecast period include product innovation, expansion into new geographic markets, ongoing clinical trials, a shift toward personalized medicine, and continued advancements in cancer research.

The rising prevalence of non-small cell lung cancer (NSCLC) is anticipated to drive the growth of the opdivo (nivolumab) market in the coming years. NSCLC is the most prevalent form of lung cancer, representing approximately 85% of all lung cancer cases. The growing incidence of NSCLC can mainly be attributed to factors such as smoking, exposure to environmental pollutants, genetic mutations, and a family history of cancer. Opdivo functions by blocking the PD-1 receptor on immune cells, boosting the body's immune response to identify and attack cancer cells. For instance, in 2024, the American Cancer Society, a U.S.-based health organization, reported 234,580 new lung cancer cases diagnosed in the U.S., with 80% of those being NSCLC, showing an increase compared to 2023, when 238,340 people were diagnosed with lung cancer. Therefore, the rising incidence of non-small lung cancer is fueling the expansion of the opdivo (nivolumab) market.

A significant trend in the opdivo (nivolumab) market is the development of combination therapies to enhance treatment efficacy and broaden its use across various cancer types. These combination strategies aim to address resistance mechanisms and offer more comprehensive treatment alternatives for advanced cancer patients. For example, in October 2024, the U.S.-based Food and Drug Administration approved Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab post-surgery as adjuvant treatment for adults with resectable NSCLC. This approval allows Opdivo to be used in conjunction with platinum-doublet chemotherapy before surgery and as monotherapy afterward for patients without known EGFR or ALK mutations.

In November 2022, Lyvgen Biopharma, a biotech firm based in China, entered into a partnership with Bristol Myers Squibb (BMS). This collaboration aims to conduct a Phase II clinical trial assessing LVGN7409 in combination with Opdivo (nivolumab) for patients with advanced or metastatic NSCLC. Bristol Myers Squibb is the pharmaceutical company responsible for developing Opdivo (nivolumab).

Major players operating in the opdivo (nivolumab) market are Bristol-Myers Squibb, Ono Pharmaceutical.

North America was the largest region in the 0pdivo (nivolumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in opdivo (nivolumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the opdivo (nivolumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Opdivo (nivolumab) is a prescription medication classified as an immune checkpoint inhibitor, specifically targeting programmed death-1 (PD-1) receptors. It is a form of immunotherapy used to treat various types of cancer by enhancing the body's immune system to recognize and eliminate cancer cells.

The primary formulations available in the opdivo (nivolumab) market include 40 mg/4 ml, 100 mg/10 ml, and 240 mg/24 ml. The 40 mg/4 ml dosage is a lower concentration, intended for patients who need smaller doses, typically used in specific treatment protocols or for patients with lower body weight. These formulations are available in various forms, including injections and solutions, and are used across different age groups, including both adults and pediatric patients. Opdivo is applied in the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, classical Hodgkin lymphoma (CHL), squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), and other cancers. The primary end-users of Opdivo are hospitals, clinics, and other healthcare settings.

The opdivo (nivolumab) market research report is one of a series of new reports that provides opdivo (nivolumab) market statistics, including opdivo (nivolumab) industry global market size, regional shares, competitors with a opdivo (nivolumab) market share, detailed opdivo (nivolumab) market segments, market trends, and opportunities, and any further data you may need to thrive in the opdivo (nivolumab) industry. This opdivo (nivolumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The opdivo (nivolumab) market consists of sales of monotherapy and combination therapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.